444 related articles for article (PubMed ID: 24709958)
1. Role of receptor tyrosine kinases and their ligands in glioblastoma.
Carrasco-García E; Saceda M; Martínez-Lacaci I
Cells; 2014 Apr; 3(2):199-235. PubMed ID: 24709958
[TBL] [Abstract][Full Text] [Related]
2. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Lokker NA; Sullivan CM; Hollenbach SJ; Israel MA; Giese NA
Cancer Res; 2002 Jul; 62(13):3729-35. PubMed ID: 12097282
[TBL] [Abstract][Full Text] [Related]
3. Development of targeted therapies in treatment of glioblastoma.
Xu YY; Gao P; Sun Y; Duan YR
Cancer Biol Med; 2015 Sep; 12(3):223-37. PubMed ID: 26487967
[TBL] [Abstract][Full Text] [Related]
4. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
[TBL] [Abstract][Full Text] [Related]
5. Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Camorani S; Crescenzi E; Colecchia D; Carpentieri A; Amoresano A; Fedele M; Chiariello M; Cerchia L
Oncotarget; 2015 Nov; 6(35):37570-87. PubMed ID: 26461476
[TBL] [Abstract][Full Text] [Related]
6. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
[TBL] [Abstract][Full Text] [Related]
7. PDGFR and IGF-1R Inhibitors Induce a G2/M Arrest and Subsequent Cell Death in Human Glioblastoma Cell Lines.
Carrasco-Garcia E; Martinez-Lacaci I; Mayor-López L; Tristante E; Carballo-Santana M; García-Morales P; Ventero Martin MP; Fuentes-Baile M; Rodriguez-Lescure Á; Saceda M
Cells; 2018 Sep; 7(9):. PubMed ID: 30200644
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the insulin-like growth factor 1 receptor by CHM-1 blocks proliferation of glioblastoma multiforme cells.
Lin YC; Hou SC; Hung CM; Lin JN; Chen WC; Ho CT; Kuo SC; Way TD
Chem Biol Interact; 2015 Apr; 231():119-26. PubMed ID: 25643584
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor receptor and ligand family expression and activity in glioblastoma.
von Achenbach C; Weller M; Szabo E
J Neurochem; 2018 Oct; 147(1):99-109. PubMed ID: 29953622
[TBL] [Abstract][Full Text] [Related]
10. Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.
Bolcaen J; Nair S; Driver CHS; Boshomane TMG; Ebenhan T; Vandevoorde C
Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34209513
[TBL] [Abstract][Full Text] [Related]
11. Targeting ErbB receptors in high-grade glioma.
Berezowska S; Schlegel J
Curr Pharm Des; 2011; 17(23):2468-87. PubMed ID: 21827413
[TBL] [Abstract][Full Text] [Related]
12. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
Chakravarti A; Loeffler JS; Dyson NJ
Cancer Res; 2002 Jan; 62(1):200-7. PubMed ID: 11782378
[TBL] [Abstract][Full Text] [Related]
14. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
[TBL] [Abstract][Full Text] [Related]
15. The TICking clock of EGFR therapy resistance in glioblastoma: Target Independence or target Compensation.
Saleem H; Kulsoom Abdul U; Küçükosmanoglu A; Houweling M; Cornelissen FMG; Heiland DH; Hegi ME; Kouwenhoven MCM; Bailey D; Würdinger T; Westerman BA
Drug Resist Updat; 2019 Mar; 43():29-37. PubMed ID: 31054489
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
Kalman B; Szep E; Garzuly F; Post DE
Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
[TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
18. Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.
Montor WR; Salas AROSE; Melo FHM
Mol Cancer; 2018 Feb; 17(1):55. PubMed ID: 29455659
[TBL] [Abstract][Full Text] [Related]
19. Mer receptor tyrosine kinase inhibition impedes glioblastoma multiforme migration and alters cellular morphology.
Rogers AE; Le JP; Sather S; Pernu BM; Graham DK; Pierce AM; Keating AK
Oncogene; 2012 Sep; 31(38):4171-81. PubMed ID: 22179835
[TBL] [Abstract][Full Text] [Related]
20. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
